

Transformative Tools for Neural Access, Delivery, & Performance

INITIAL CLINICAL MARKET

Improving DBS Probe Placement – Minimizing Revision Surgeries for Treatment Resistant Neurological Conditions

Since 2006, Actuated Medical has been dedicated to improving patient outcomes by integrating motion into medical devices. Developed with \$18M in non-dilutive funding, our **NeuralGlider®** technology uses gentle oscillation for less invasive brain implant insertion and targeted drug delivery. We're tapping into multi-billion-dollar neurological disease treatment markets – including treatment-resistant addiction, depression and Parkinson's Disease. Our **NeuralGlider Inserter** inserts brain implants with greater precision and less tissue damage to improve implant performance and longevity. The **NeuralGlider Injector** enables targeted drug delivery deep into the brain with finer, less invasive needles to minimize tissue trauma and medication loss for brain cancer treatment, AAV-gene therapy infusion, and addiction treatments. 43+ third-party publications citing NeuralGlider are strengthening the scientific foundation to transition to clinical indications. Our first clinical indication intends to improve deep brain stimulation (DBS) probe insertion, reducing clinician variability and the need for revision surgeries, demonstrated initially in Parkinson's patients.



100M+ People globally have treatment resistant neurological conditions, such as Parkinson's Disease, epilepsy, obsessive-compulsive disorder (OCD), and depression.

DBS can give them their lives back, when other treatments fail.

Complex tissue dynamics result from the many different tissue layers in the brain that the probe transverses. Therefore, as DBS probes are inserted, 3-8% of the time the probe tip misses the target (~1 in 20 patients), or shifts after the tip is put in place, leading to off target effects, sub-optimal treatment, or potentially a costly second brain surgery.

NeuralGlider uses patented gentle oscillating technology and a coupling mechanism to insert brain implants precisely with less force and damage to tissue.

Preclinical studies have shown the ability to hit small targets in the brain more accurately resulting in improved implant performance and outcomes.



DBS, BCI Systems, Next Gen Probes



DBS
\$1.5B

CAGR
9.8%

Addiction, Gene Therapy, Cancer Medication Infusion



AAV
\$3.9B

CAGR
40.1%



\$50M+ Non-Dilutive Capital



9 FDA 510(k) Clearances

45 US & Intl Patents

11 Registered Trademarks

ISO 13485 Certified



20,000 sq ft Facility

2006 est. PA C-Corp

Management Team



Maureen Mulvihill, PhD
President & CEO

Board Member of



Roger Bagwell, PhD
Director, Neural Device Operations



Douglas Dillon, MS
Director, QA & RA



Ian Charney
Director, Manufacturing



Christian Haller
Advisor

MAB

11 Members

BOD

5 Members

Keiretsu Key Deal Terms

- + \$10M Series A
- + Participating Preferred Shares
- + Warrants Discounted 50%
- + \$25k Minimum Investment
- + QSBS Entity Structure
- + \$25M Pre-Money Valuation

Let's Talk!

Maureen L. Mulvihill, PhD | CEO
maureen@actuatedmedical.com
814.355.0003 x100

ActuatedMedical.com